Rapid Micro Biosystems reported second quarter 2026 revenue of $8.1 million, up 11% year-over-year. The life sciences technology company achieved a milestone with its 200th Growth Direct system placed globally, adding four new systems and completing nine validations during the quarter. Consumable revenue grew more than 20% year-over-year, whilst recurring revenue increased 14% to comprise 63% of total revenue. Gross margin reached a record 15%, up 11 percentage points from the prior year period. The company posted a net loss of $12.9 million, or $0.27 per share, compared to a net loss of $11.9 million in the same quarter last year. Cash and short-term investments totalled approximately $20 million at quarter end. Rapid Micro reaffirmed full-year 2026 revenue guidance of $37 million to $41 million.

Rapid Micro Biosystems to announce second quarter 2026 financial results on August 7, 2026. MWN-AI** Summary. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), a leader in life sciences technology, is set to announce its financial results for the second quarter of 2026 on August 7, 2026. The announcement will occur before the market opens, with a subsequent conference call scheduled for 8:30 a.m. ET the same day. This call, hosted by the Company's management team, will provide investors and stakeholders an opportunity to gain insights into the Company's performance and future outlook. Interested parties can access the live audio webcast through the Company's website, with a replay available after the event. As an innovative provider of automation solutions for the healthcare sector, Rapid Micro Biosystems focuses on enhancing the manufacturing processes of critical products, including biologics, vaccines, and gene therapies. Their flagship product, the Growth Direct system, revolutionizes microbial quality control (MQC) testing by automating and modernizing traditional and often slow manual testing procedures. This system is designed to streamline operations in complex pharmaceutical manufacturing settings, enabling faster and more accurate results. Through the implementation of MQC automation, the Growth Direct system improves operational efficiency and compliance with stringent data integrity regulations, significantly accelerating decision-making processes for healthcare manufacturers. Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems also maintains a U.S. manufacturing facility in Lowell, and has expanded its global footprint with locations in Switzerland, Germany, and the Netherlands. The Company's commitment to innovation and efficiency positions it as a vital player in the fast-evolving landscape of healthcare product manufacturing. For additional information, investors and interested parties can visit their website or connect on social media platforms. MWN-AI** Analysis. As Market Wire News approach the anticipated release of Rapid Micro Biosystems' second quarter 2026 financial results on August 7, 2026, investors should carefully consider the implications of the company's performance in light of market conditions and its technological advancements. The life sciences sector continues to experience robust growth, driven by increasing demand for automation solutions in pharmaceutical manufacturing. Rapid Micro Biosystems stands out with its flagship Growth Direct system, which modernizes microbial quality control (MQC) processes, offering enhanced efficiency and compliance for manufacturing operations. Investors should monitor several key indicators during the earnings announcement. First, revenue growth figures will be crucial, as they reflect the capacity of the Growth Direct system to capture market share. Analysts will likely focus on year-over-year growth and sequential improvements compared to the previous quarter. The operational efficiency of the company's solutions in facilitating faster and safer healthcare product releases could serve as a strong driver for revenue and customer retention. Additionally, it's prudent for investors to listen closely to management's commentary on industry trends, competitive positioning, and any updates regarding partnerships or contracts that may signal the company's future trajectory. With heightened scrutiny on data integrity and regulatory compliance in the life sciences industry, Rapid Micro's value proposition becomes even more compelling. Lastly, investors should gauge the company's ability to manage costs and enhance margins, especially in light of potential economic headwinds affecting the broader market. If Rapid Micro Biosystems can demonstrate strong financial health and provide optimistic guidance for the upcoming quarters, it could bolster investor confidence and position the stock favorably in this niche but growing market. Overall, with ongoing advancements in healthcare technology, Rapid Micro Biosystems presents a promising investment opportunity, contingent on its upcoming performance metrics and strategic insights shared during the earnings call. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. July 23, 2026 05:15:26 pm LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) - Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2026 financial results prior to the market open on Friday, August 7, 2026. In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 7, 2026. The live audio webcast will be accessible on the Company's website and can be accessed with this link. The webcast will be archived and available for replay after the event. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ("MQC") testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn. Investor Contact:Michael Beaulieu, CFAVice President, Investor Relations and Corporate [email protected] Contact:[email protected] FAQ**. What key financial metrics should investors watch for in the upcoming Q2 2026 earnings release from Rapid Micro Biosystems Inc. (RPID)? Investors should closely monitor Rapid Micro Biosystems Inc.'s revenue growth, gross margin, operating expenses, net income or loss, cash flow from operations, and guidance for future quarters during the Q2 2026 earnings release. How has the performance of the Growth Direct system impacted the growth and operational efficiency of Rapid Micro Biosystems Inc. (RPID) in recent quarters? The Growth Direct system has significantly enhanced Rapid Micro Biosystems Inc.'s operational efficiency and accelerated growth by streamlining microbial testing processes, leading to improved product offerings and customer satisfaction in recent quarters. What strategic initiatives is Rapid Micro Biosystems Inc. (RPID) planning to implement following the Q2 2026 earnings call to drive future revenue growth? As of my last update in October 2023, I do not have specific insights into Rapid Micro Biosystems Inc.'s plans following the Q2 2026 earnings call, but typically companies focus on product innovation, market expansion, strategic partnerships, and enhanced customer engagement to drive growth. Can you provide insights into the competitive landscape for Rapid Micro Biosystems Inc. (RPID) in the life sciences automation market as it relates to the upcoming results and future outlook? Rapid Micro Biosystems Inc. (RPID) faces a competitive landscape characterized by emerging automation technologies and heightened demand for efficient life sciences processes, with upcoming results expected to reflect its strategic positioning and growth potential in this dynamic market. **MWN-AI FAQ is based on asking OpenAI questions about Rapid Micro Biosystems Inc. (NASDAQ: RPID).

Rapid Micro Biosystems has raised $32 million through an underwritten offering of 3.58 million shares of Class A common stock and accompanying warrants. The offering includes pre-funded warrants, Series A and Series B warrants. The round was led by Bain Capital Life Sciences and Armistice Capital. Additionally, certain officers and directors have agreed to purchase 71,607 shares of Class A common stock and warrants through a separate securities purchase agreement.